Curocell Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cost of Revenue	19.6	10.49	14.19
Gross Profit	-19.6	-10.49	-14.19
Selling, General & Admin	4,623	4,632	3,821
Research & Development	31,251	31,864	27,191
Amortization of Goodwill & Intangibles	87.46	3.87	1.5
Other Operating Expenses	185.29	14.51	11.22
Operating Expenses	36,270	36,614	31,116
Operating Income	-36,290	-36,624	-31,130
Interest Expense	-4,544	-2,603	-2,431
Interest & Investment Income	457.72	938.26	617.54
Currency Exchange Gain (Loss)	37.42	-24.34	-14.64
Other Non Operating Income (Expenses)	-5,976	83.35	3,305
EBT Excluding Unusual Items	-46,314	-38,230	-29,652
Gain (Loss) on Sale of Assets	9.17	-8.18	-11.24
Pretax Income	-46,305	-38,238	-29,664
Income Tax Expense	-	1.1	-88.73
Net Income	-46,305	-38,239	-29,575
Net Income to Common	-46,305	-38,239	-29,575
Shares Outstanding (Basic)	14	14	12
Shares Outstanding (Diluted)	14	14	12
Shares Change (YoY)	2.51%	18.11%	-
EPS (Basic)	-3232.00	-2736.00	-2499.18
EPS (Diluted)	-3232.00	-2736.00	-2499.18
Free Cash Flow	-30,306	-28,973	-46,428
Free Cash Flow Per Share	-2115.32	-2072.99	-3923.32
EBITDA	-30,168	-30,289	-26,424
D&A For EBITDA	6,122	6,335	4,706
EBIT	-36,290	-36,624	-31,130
Advertising Expenses	70.63	43.48	45.38

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.